Arrowhead receives $25M milestone payment from Amgen for heart disease treatment
Arrowhead Pharma (NASDAQ:ARWR) said on Tuesday it had received $25M milestone payment from Amgen (NASDAQ:AMGN), asÂ it enrolled first subject for its Phase 3 trial of olpasiran.
Arrowhead is further eligible to receive up to an additional $535M in aggregate development, regulatory, and sales milestone payments from Amgen and Royalty Pharma plc (NASDAQ:RPRX).  Olpasiran was originally developed by Arrowhead using its Targeted RNAi Molecule, or TRiM, platform and was licensed to Amgen in 2016.
It is designed to lower levels of lipoprotein(a), a genetically determined risk factor for cardiovascular disease.